Skip to content Skip to left sidebar Skip to footer

COVID-19 Vaccine

Persons Authorized to Administer COVID-19 Vaccinations

Persons Authorized to Administer COVID-19 Vaccinations

Who can administer COVID-19 Vaccine in Pennsylvania?

Below is a comprehensive list of all potential COVID-19 vaccinators in Pennsylvania, by license type as of February 9th, 2021. The chart is broken down by license and the PA legal authority that is applicable to whether they may be able to administer vaccines.

There are other licenses that can have their scope of practice incorporate additional skills, such as an emergency medical responder, if the skills are approved by the Department and are published in the Pennsylvania Bulletin. 28 Pa. Code section 1023.24.  Possible amendments to the PREP Act may also expand the ability of a license to administer vaccines in the Commonwealth.

To view or download a pdf copy of the document, please click here.

General COVID-19 Vaccine FAQ Sheet

General COVID-19 Vaccine FAQ Sheet

The Philadelphia Immunization Program has received many questions from residents about the Pfizer and Moderna COVID-19 Vaccines. It the vaccine safe? Is it effective? What are the side effects?

To help answer these questions, we have created a General COVID-19 Vaccine FAQ sheet in seven different languages. The FAQ sheet compiles the ten most frequently asked questions about the Pfizer and Moderna COVID-19 vaccine by Philadelphia residents. Please select and download one of the files below and share it among your network.

PDPH has also created more specific FAQ sheets for childcare workers, congregate living facility staff and residents, essential workers, food service workers, long term care facility (LCTF) staff and residents, pregnant people, and public transit workers. Please click here to access the specific FAQ sheets.

Don’t see your question listed? Please visit the city’s COVID-19 webpage for more FAQs and updates about the vaccine. Thank you for all you do to help keep Philadelphia safe and healthy!

Medical Personnel COVID-19 Vaccine Contact Form for Philadelphia Residents

Medical Personnel COVID-19 Vaccine Contact Form for Philadelphia Residents

Our medical personnel contact form has been replaced with a COVID-19 Vaccine Interest Form.

Please fill out our COVID-19 Vaccine Interest Form for Philadelphia Residents and submit your contact information. We will connect you with where to register to receive your COVID-19 vaccine in the near future.

Healthcare Workers Seeking COVID-19 Immunization

Healthcare Workers Seeking COVID-19 Immunization

To download a pdf copy of the document, please click here.

Immunization with a safe and effective COVID-19 vaccine is a critical component of the national strategy to reduce morbidity and mortality from the SARS-CoV-2 virus, and to help restore societal functioning. While the goal is to offer COVID-19 vaccine to all people who wish to be vaccinated, there is currently a limited supply of vaccine available. Initial vaccination efforts are focusing on healthcare workers who have a high risk of exposure to the virus and are at risk of transmitting infection to vulnerable persons. Residents of longterm care facilities are also a top priority. If you are a healthcare worker with both a risk of exposure and a risk of transmitting COVID-19, you are eligible to receive COVID-19 vaccination, as follows:

  • If you are affiliated with a Philadelphia hospital or health system, check with their Occupational Health Services to learn when vaccine will be made available to your practice.
  • If you are not affiliated with a hospital or health system, you will be able to receive vaccine through a local Pharmacy, Clinic, or Urgent Care. Access to vaccine at these sites will be appointment-based and for Philadelphia providers only. The ultracold storage requirements of Pfizer COVID vaccine makes this impossible to provide in these types of venues. When another product becomes available, it will be made available. Check back weekly for updates.
  • If you are not affiliated with a hospital or health system, and have a large practice (>100 employees), you may be eligible to receive a direct shipment of vaccine for your employees. To qualify for receiving shipped vaccine, you must: (1) be located in Philadelphia; (2) sign and submit the CDC Provider Agreement form at https://vax.phila.gov/index.php/covid-19/ ; and (3) be able to transmit electronic vaccine administration records to the city’s data system (submit inquiry to
    Philavax@phila.gov).

 

If you have any questions, contact our team at vaccines@phila.gov.

Enroll your site to be a COVID-19 Vaccine Provider

Enroll your site to be a COVID-19 Vaccine Provider

COVID-19 Vaccine Provider Agreement Form

Our COVID-19 Provider Agreement form is here!

All sites intending to distribute COVID-19 vaccine must enroll as a provider. All medical facilities who regularly provide vaccine are eligible to enroll into our COVID-19 vaccine program.

Please refer to our Provider Agreement Guide to enroll as a provider for the COVID-19 vaccine.

Please review the Provider Agreement Guide in its entirety before filling out the agreement form and survey.

The agreement and survey form can be accessed here.

If you have any questions, contact our team at vaccines@phila.gov.

ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine

ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine

12/13/2020 The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. 

Below is a summary of the report. To read the report in full, please click here.

On December 11, 2020, the Food and Drug Administration issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine. On December 12, 2020, after an explicit, evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP’s interim recommendation for allocating initial supplies of COVID-19 vaccines.

Vaccinating Pregnant and Lactating Patients Against COVID-19

Vaccinating Pregnant and Lactating Patients Against COVID-19

12/13/2020 Vaccinating Pregnant and Lactating Patients Against COVID-19

Below is an excerpt from the American College of Obstetricians and Gynecologist’s (ACOG) recommendations for vaccinating Pregnant and Lactating Patients against COVID-19. To read the full article, click here.

ACOG Recommendations

Pregnant Individuals

ACOG recommends that COVID-19 vaccines should not be withheld from pregnant individuals who meet criteria for vaccination based on ACIP-recommended priority groups. While safety data on the use of COVID-19 vaccines in pregnancy are not currently available, there are also no data to indicate that the vaccines should be contraindicated, and no safety signals generated from DART studies for the Pfizer-BioNtech vaccine. Therefore, in the interest of allowing pregnant individuals who would otherwise be considered a priority population for a vaccine approved for use under EUA, make their own decisions regarding their health, ACOG recommends that pregnant individuals should be free to make their own decision in conjunction with their clinical care team.

Individuals considering a COVID-19 vaccine should have access to available information about the safety and efficacy of the vaccine, including information about data that are not available. A conversation between the patient and their clinical team may assist with decisions regarding the use of vaccines approved under EUA for the prevention of COVID-19 by pregnant patients.  Important considerations include the level of activity of the pandemic in the community, the potential efficacy of the vaccine, the potential risk and severity of maternal disease, including the effects of disease on the fetus and newborn, and the safety of the vaccine for the pregnant patient and the fetus. While a conversation with a clinician may be helpful, it should not be required prior to vaccination as this may cause unnecessary barriers to access.

Clinicians should review the available data on risks and benefits of vaccination with pregnant patients, including the risks of not getting vaccinated in the context of the individual patient’s current health status, and risk of exposure, including the possibility for exposure at work or home and the possibility for exposing high-risk household members. Conversations about risk should take in to account the individual patient’s values and perceived risk of various outcomes and should respect and support autonomous decision-making (ACOG 2013).

Pregnant women who experience fever following vaccination should be counseled to take acetaminophen, as fever has been associated with adverse pregnancy outcomes. Acetaminophen has been proven to be safe for use in pregnancy and does not appear to impact antibody response to COVID-19 vaccines.

Pregnant patients who decline vaccination should be supported in their decision. Regardless of their decision to receive or not receive the vaccine, these conversations provide an opportunity to remind patients about the importance of other prevention measures such as hand washing, physical distancing, and wearing a mask.

Lactating Individuals

ACOG recommends COVID-19 vaccines be offered to lactating individuals similar to non-lactating individuals when they meet criteria for receipt of the vaccine based on prioritization groups outlined by the ACIP. While lactating individuals were not included in most clinical trials, COVID-19 vaccines should not be withheld from lactating individuals who otherwise meet criteria for vaccination. Theoretical concerns regarding the safety of vaccinating lactating individuals do not outweigh the potential benefits of receiving the vaccine. There is no need to avoid initiation or discontinue breastfeeding in patients who receive a COVID-19 vaccine.

Individuals Contemplating Pregnancy

Vaccination is strongly encouraged for non-pregnant individuals within the ACIP prioritization group(s). Further, ACOG recommends vaccination of individuals who are actively trying to become pregnant or are contemplating pregnancy and meet the criteria for vaccination based on ACIP prioritization recommendations. Additionally, it is not necessary to delay pregnancy after completing both doses of the COVID-19 vaccine.

If an individual becomes pregnant after the first dose of the COVID-19 vaccine series, the second dose should be administered as indicated. If an individual receives a COVID-19 vaccine and becomes pregnant within 30 days of receipt of the vaccine, participation in CDC’s V-SAFE program should be encouraged (see below for more information on CDC’s V-SAFE program).

Importantly, routine pregnancy testing is not recommended prior to receiving a COVID-19 vaccine.

Stakeholder COVID-19 Vaccine Emergency Use Agreement (EUA) FAQ

Stakeholder COVID-19 Vaccine Emergency Use Agreement (EUA) FAQ

12/11/2020 Stakeholder COVID-19 Vaccine Emergency Use Agreement (EUA) FAQ

The CDC has shared an Emergency Use Authorization (EUA) FAQ for COVID-19 Vaccine Stakeholders. To view as a document, click here.

 

Will a prescription be necessary for a vaccine under an EUA?
As of December 9, 2020, no EUAs have been issued to authorize the use of COVID-19 vaccines. If EUAs are issued for COVID-19 vaccines, it is expected that those vaccines may be administered without the requirement for an individual prescription for each vaccine recipient from an authorized healthcare provider. Under an EUA, FDA has an option to waive prescription requirements, if appropriate, depending on the authorized product specifics, authorized use, and/or emergency circumstances. In addition to an EUA, other legal authorities and/or plans may apply to vaccine administration:

  • Legal authorities for relevant emergency response agencies (e.g., state, local, tribal and territorial health departments, healthcare professional licensing boards);
  •  Standing orders issued by a state health officer or applicable medical control officials or an executive order issued by a governor to authorize certain healthcare providers (e.g., nurses, pharmacists) to administer COVID-19 vaccine;
  • State COVID-19 vaccination and emergency response plans; and
  • DC’s COVID-19 Vaccination Program.

Does an EUA have any impact on standing orders?
Standing orders are a type of medical order authorized or allowed under state laws. They permit the delegation and delivery of healthcare services through standardized criteria and procedures. Standing orders are one mechanism to enable non-physician healthcare providers (e.g., nurses, pharmacists) to assess and vaccinate persons who meet the criteria for vaccination without requiring a direct, individual order each time.

During emergencies, states might use other legal mechanisms to facilitate vaccine administration, such as executive orders, emergency regulations, or position statements from licensing boards. FDA does not issue standing orders. However, it is expected that EUAs for COVID-19 vaccines would allow flexibility so that states could use their own mechanisms, like standing orders, to authorize appropriate healthcare providers to administer COVID-19 vaccine(s). States should review any applicable authorizations of certain healthcare providers to administer COVID-19 vaccine under the Public Readiness and Emergency Preparedness (PREP) Act Declaration for Medical Countermeasures against COVID-19 (e.g., qualified pharmacy technicians and state-authorized pharmacy interns acting under the supervision of a qualified pharmacist). It is also expected that vaccine administration would be in accordance with the stakeholder’s official COVID-19 vaccination and emergency response plans and that vaccination providers would be enrolled in the CDC COVID-19 Vaccination Program.

Statutes and regulations regarding the use of standing orders (or similar mechanisms) vary by state. States should review their statutory and regulatory language to ensure standing orders can cover the administration of an unlicensed vaccine that has been authorized by FDA for emergency use under an EUA. Specifically, states should ensure that state law does not preclude the use of standing orders for an investigational product authorized under an EUA. States should also ensure their state laws permit the administration of COVID-19 vaccines intended to be used under EUAs (i.e., the language of the state’s laws is either broad enough to include COVID-19 vaccines or specifically lists the COVID-19 vaccines, depending on how the state’s laws are written) and that COVID-19 vaccines are administered within the scope of authorized use under the applicable EUA.

Can a COVID-19 vaccine be administered to populations not included in the authorized use of the vaccine under its EUA?No. Use of any vaccine in populations outside the scope of its EUA

would be an unauthorized use of the vaccine. Each EUA issued by FDA will describe the scope of the vaccine’s authorized use, including populations (e.g., age groups) to which the vaccine may be administered. The scope of what is authorized under each EUA will be based on the available safety and efficacy data from populations studied in clinical trials.

In order for liability protections under the Public Readiness and Emergency Preparedness (PREP) Act to apply, the use of the vaccine must be under an appropriate regulatory mechanism (e.g., an EUA, investigational new drug application, or approved biologics license application). Therefore, if a vaccine is authorized for use under an EUA, any use beyond the scope of what is described in the EUA would not be eligible for applicable liability protections under the PREP Act or injury compensation available under the Countermeasures Injury Compensation Program.

CMS Acts to Ensure Coverage of COVID-19 Vaccines & Therapeutics

CMS Acts to Ensure Coverage of COVID-19 Vaccines & Therapeutics

10/29/20 CMS Acts to Ensure Coverage of COVID-19 Vaccines & Therapeutics
Centers for Medicare & Medicaid Services (CMS) just released new Medicare payment rates for COVID-19 vaccine administration. The Medicare payment rates will be $28.39 to administer single-dose vaccines. For a COVID-19 vaccine requiring a series of two or more doses, the initial dose(s) administration payment rate will be $16.94, and $28.39 for the administration of the final dose in the series. These rates will be geographically adjusted and recognize the costs involved in administering the vaccine, including the additional resources involved with required public health reporting, conducting important outreach and patient education, and spending additional time with patients answering any questions they may have about the vaccine. Medicare beneficiaries, those in Original Medicare or enrolled in Medicare Advantage, will be able to get the vaccine at no cost.

Want updates sent right to your inbox? Email vaccines@phila.gov to join the Philadelphia Immunization Program’s COVID-19 vaccine mailing list.